New imaging agent could sharpen cancer treatment decisions
NCT ID NCT07168785
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase study will test a new radioactive tracer called [18F]-AraG in just 5 people with advanced head and neck cancer. Participants will receive two PET/CT scans (before and during standard chemoradiotherapy) to see if the tracer's uptake matches immune cell activity and predicts treatment response. The goal is to improve risk assessment, not to treat the cancer directly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]-AraG radiotracer (a radioactive dye for PET scans)
What this could lead to
If successful, this could lead to a more accurate way to predict how well head and neck cancer responds to chemoradiotherapy, helping doctors tailor treatment.
What could go wrong
This is a very early, tiny study (only 5 people) testing a new imaging agent. It is not designed to prove the tracer improves outcomes, only to see if it correlates with immune activity and response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University
Indianapolis, Indiana, 46202, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact